Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abreva overseas

This article was originally published in The Tan Sheet

Executive Summary

Cairo, Egypt-based Biopharm Group will manufacture, market Avanir Pharmaceuticals' docosanol 10% cream in Egypt, other Middle East countries under licensing agreement announced Jan. 30. San Diego-based Avanir will receive milestone payments, product sale royalties; marketing approvals are expected to take approximately 18 months. Regulatory approvals in Canada, where cream will be marketed by GlaxoSmithKline, Israel (CTS Chemical) and South Korea (Boryung) expected in second or third quarter. Firm has entered research collaboration with Shanghai Asiatic Pharmaceutical (China) for clinical trials on genital herpes, herpes labialis, herpes zoster (shingles)...

Topics

UsernamePublicRestriction

Register

PS093560

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel